These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

543 related items for PubMed ID: 21233607

  • 1. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
    van Heijl M, Omloo JM, van Berge Henegouwen MI, Hoekstra OS, Boellaard R, Bossuyt PM, Busch OR, Tilanus HW, Hulshof MC, van der Gaast A, Nieuwenhuijzen GA, Bonenkamp HJ, Plukker JT, Cuesta MA, Ten Kate FJ, Pruim J, van Dekken H, Bergman JJ, Sloof GW, van Lanschot JJ.
    Ann Surg; 2011 Jan; 253(1):56-63. PubMed ID: 21233607
    [Abstract] [Full Text] [Related]

  • 2. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus.
    Malik V, Lucey JA, Duffy GJ, Wilson L, McNamara L, Keogan M, Gillham C, Reynolds JV.
    J Nucl Med; 2010 Dec; 51(12):1863-9. PubMed ID: 21078796
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
    Kukar M, Alnaji RM, Jabi F, Platz TA, Attwood K, Nava H, Ben-David K, Mattson D, Salerno K, Malhotra U, Kanehira K, Gannon J, Hochwald SN.
    JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
    [Abstract] [Full Text] [Related]

  • 5. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment.
    Wieder HA, Brücher BL, Zimmermann F, Becker K, Lordick F, Beer A, Schwaiger M, Fink U, Siewert JR, Stein HJ, Weber WA.
    J Clin Oncol; 2004 Mar 01; 22(5):900-8. PubMed ID: 14990646
    [Abstract] [Full Text] [Related]

  • 6. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography.
    Brücher BL, Weber W, Bauer M, Fink U, Avril N, Stein HJ, Werner M, Zimmerman F, Siewert JR, Schwaiger M.
    Ann Surg; 2001 Mar 01; 233(3):300-9. PubMed ID: 11224616
    [Abstract] [Full Text] [Related]

  • 7. Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma.
    Konski AA, Cheng JD, Goldberg M, Li T, Maurer A, Yu JQ, Haluszka O, Scott W, Meropol NJ, Cohen SJ, Freedman G, Weiner LM.
    Int J Radiat Oncol Biol Phys; 2007 Oct 01; 69(2):358-63. PubMed ID: 17532577
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Utility of 18F-FDG PET for Predicting Histopathologic Response in Esophageal Carcinoma following Chemoradiation.
    Arnett ALH, Merrell KW, Macintosh EM, James SE, Nathan MA, Shen KR, Ravi K, Neben Wittich MA, Haddock MG, Hallemeier CL.
    J Thorac Oncol; 2017 Jan 01; 12(1):121-128. PubMed ID: 27569732
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.
    Lorenzen S, von Gall C, Stange A, Haag GM, Weitz J, Haberkorn U, Lordick F, Weichert W, Abel U, Debus J, Jäger D, Münter MW.
    BMC Cancer; 2011 Jun 24; 11():266. PubMed ID: 21702914
    [Abstract] [Full Text] [Related]

  • 12. Pilot study of serial FLT and FDG-PET/CT imaging to monitor response to neoadjuvant chemoradiotherapy of esophageal adenocarcinoma: correlation with histopathologic response.
    Gerbaudo VH, Killoran JH, Kim CK, Hornick JL, Nowak JA, Enzinger PC, Mamon HJ.
    Ann Nucl Med; 2018 Apr 24; 32(3):165-174. PubMed ID: 29332233
    [Abstract] [Full Text] [Related]

  • 13. Intratreatment Response Assessment With 18F-FDG PET: Correlation of Semiquantitative PET Features With Pathologic Response of Esophageal Cancer to Neoadjuvant Chemoradiotherapy.
    Tandberg DJ, Cui Y, Rushing CN, Hong JC, Ackerson BG, Marin D, Zhang X, Czito BG, Willett CW, Palta M.
    Int J Radiat Oncol Biol Phys; 2018 Nov 15; 102(4):1002-1007. PubMed ID: 30055238
    [Abstract] [Full Text] [Related]

  • 14. 18F-FDG PET Response After Induction Chemotherapy Can Predict Who Will Benefit from Subsequent Esophagectomy After Chemoradiotherapy for Esophageal Adenocarcinoma.
    Xi M, Liao Z, Hofstetter WL, Komaki R, Ho L, Lin SH.
    J Nucl Med; 2017 Nov 15; 58(11):1756-1763. PubMed ID: 28522744
    [Abstract] [Full Text] [Related]

  • 15. Usefulness of 18f-Fluorodeoxyglucose Positron Emission Tomography for Predicting the Pathological Response of Neoadjuvant Chemoradiotherapy for T4 Esophageal Squamous Cell Carcinoma.
    Sakai M, Sohda M, Miyazaki T, Honjo H, Hara K, Ozawa D, Suzuki S, Tanaka N, Yokobori T, Kuwano H.
    Hepatogastroenterology; 2015 Jun 15; 62(140):898-901. PubMed ID: 26902024
    [Abstract] [Full Text] [Related]

  • 16. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma.
    Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, Cox JD, Komaki RR, Hong D, Lee HK, Putnam JB, Rice DC, Smythe WR, Thai L, Vaporciyan AA, Walsh GL, Wu TT, Roth JA.
    Cancer; 2004 Oct 15; 101(8):1776-85. PubMed ID: 15386332
    [Abstract] [Full Text] [Related]

  • 17. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer.
    Levine EA, Farmer MR, Clark P, Mishra G, Ho C, Geisinger KR, Melin SA, Lovato J, Oaks T, Blackstock AW.
    Ann Surg; 2006 Apr 15; 243(4):472-8. PubMed ID: 16552197
    [Abstract] [Full Text] [Related]

  • 18. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer.
    Song SY, Kim JH, Ryu JS, Lee GH, Kim SB, Park SI, Song HY, Cho KJ, Ahn SD, Lee SW, Shin SS, Choi EK.
    Int J Radiat Oncol Biol Phys; 2005 Nov 15; 63(4):1053-9. PubMed ID: 15964705
    [Abstract] [Full Text] [Related]

  • 19. The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma.
    Klayton T, Li T, Yu JQ, Keller L, Cheng J, Cohen SJ, Meropol NJ, Scott W, Xu-Welliver M, Konski A.
    J Gastrointest Cancer; 2012 Dec 15; 43(4):612-8. PubMed ID: 22777832
    [Abstract] [Full Text] [Related]

  • 20. Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma.
    Higuchi I, Yasuda T, Yano M, Doki Y, Miyata H, Tatsumi M, Fukunaga H, Takiguchi S, Fujiwara Y, Hatazawa J, Monden M.
    J Thorac Cardiovasc Surg; 2008 Jul 15; 136(1):205-12, 212.e1-3. PubMed ID: 18603077
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.